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Breast cancer susceptibility gene 1 (BRCA1) is a tumor 
suppressor gene, and its protein BRCA1 plays a role in 
DNA repair [1]. BRCA1 is generally expressed in the cells 
of mammary glands and other tissues, helping to repair 
damaged DNA or disrupting cells when DNA cannot be 
repaired. When BRCA1 is mutated and cannot function 
and therefore the damaged DNA cannot be repaired on 
time, the risk of breast cancer will greatly increase [2]. In 
BRCA1-mutant tumors, the capability of DNA damage 
repair is decreased, which makes tumor cells sensitive 
to DNA-damaging drugs; however, high BRCA1 activity 
weakens the effect of these drugs [3].
Poly(ADP-ribose) polymerase (PARP) is an enzyme 
that detects DNA single-strand breaks and mediates 
DNA repair. The inhibition of PARP leads to the accumu-
lation of DNA fragmentation, especially in patients with 
loss of BRCA activity, and results in cells being killed by 
excessive DNA damage [4]. Preclinical models show that 
PARP inhibition selectively targets breast cancer cells 
lacking functional BRCA1 [5]. Accumulating evidence 
shows that cancer stem cells (CSCs) are responsible for 
the resistance to chemotherapeutic agents [6], but it is 
unknown whether targeted therapy (including PARP 
inhibition) has the same effect. As reported in the paper 
entitled “RAD51 mediates resistance of cancer stem cells 
to PARP inhibition in triple-negative breast cancer” [7] in 
a recent issue of Clinical Cancer Research, we found that 
PARP inhibitor (PARPi) only effectively targets BRCA1-
mutant bulk tumor cells and RAD51, a gene involved in 
DNA double-strand break repair [8], mediates this pro-
cess, but BRCA1-wild-type cancer cells and BRCA1-
mutant CSCs are resistant to PARP inhibition. RAD51 
knockdown (KD) sensitizes both BRCA1-mutant CSCs 
and BRCA1-wild-type cells to PARP inhibition. It sug-
gests an effective therapeutic intervention for targeting 
triple-negative breast cancer (TNBC).
In this study, we tested the cytotoxic effect of olapa-
rib (a PARPi) on four TNBC cell lines including both 
BRCA1-mutant and BRCA1-wild-type cell lines: 
SUM149, SUM159, HCC1937, and MDA-MB-231. As 
expected, PARPi treatment resulted in fewer viable cells 
in BRCA1-mutant cell lines (SUM149 and HCC1937) 
compared with those with wild-type BRCA1 (SUM159 
and MDAMB231). However, after 7 days of PARPi treat-
ment in SUM149 and HCC1937 cells, the ALDEFLUOR-
positive cells (i.e., CSCs) [9] was enriched, indicating that 
these cells were not affected by PARP inhibition. We thus 
performed an exploratory polymerase chain reaction 
array of 84 key DNA repair genes and found that RAD51 
has higher expression in CSCs than in bulk tumor cells in 
SUM149 cells. We infected SUM149 and SUM159 cells 
with a doxycycline-inducible RAD51 short-hairpin RNA 
lentiviral system. Although not affecting CSC populations 
in SUM159 cells, RAD51 KD sensitized CSCs to PARPi in 
SUM149 cells. These results support our hypothesis that 
RAD51 mediates resistance of CSCs to PARPi in BRCA1-
mutant and BRCA1-wild-type breast cancer cells.
We next determined the effects of PARP inhibition 
and RAD51 KD in an in vivo model of TNBC. The mice 
were divided into four treatment groups: vehicle control, 
olaparib, RAD51 KD (doxycycline water), and combined 
(olaparib plus RAD51 KD). For the mice injected with 
BRCA1-mutant SUM149 cells, RAD51 KD and PARP 
inhibition significantly inhibited tumor growth in the 
early stage. However, when treatment was given after 
the tumor grew to a certain stage (2  mm in diameter), 
PARP inhibition was not effective, whereas the effect 
of RAD51 KD was still significant. The combination of 
RAD51 KD and PARPi led to a more robust inhibition 
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of tumor growth. To assess the effects of PARP inhibi-
tion on the CSC frequency, serial dilutions of SUM149 
cells (control and treated) were re-injected into mouse 
mammary fat pads [10]. Compared with vehicle control, 
RAD51 KD alone and combined treatments reduced the 
CSC frequency by 70% and 90%, respectively. There is a 
consistent result in BRCA1-wild-type SUM159-injected 
mice. Together, these results indicate that our therapeutic 
regimen targets both BRCA1-mutant CSCs and BRCA1-
wild-type cells (both CSC and bulk tumor populations), 
supporting our in  vitro findings of the involvement of 
RAD51 in resistance to olaparib and, importantly, sug-
gesting an effective therapeutic intervention for targeting 
TNBC.
In conclusion, we used in  vitro models and mouse 
xenografts to demonstrate the importance of RAD51 in 
reversing PARPi resistance of CSCs in BRCA1-deficient 
and BRCA1-wild-type TNBC in this study. Our findings 
suggest that resistance to PARPi may be overcome by tar-
geting both CSCs and bulk tumor cells. To elucidate the 
clinical implications, we will further use the breast can-
cer patient-derived xenograft model to validate our cur-
rent findings. Furthermore, by targeting RAD51, it may 
be possible to greatly expand the sensitivity of TNBC to 
PARPi, beyond those with defective BRCA1 proteins. 
This novel approach holds potentials for significantly 
improved therapies for TNBC.
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